Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.7052W HIGH $20.49
Volume
916.43 K
Value Traded
11.77 M
Short % Float
10.93%
Days to Cover
7.5
-9.23%Week
-25.63%1 Month
-38.77%3 Month
+12.66%6 Month
-78.65%5 Year
+115.56%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
941.05 M
EPS (TTM)
0.17
P/E Ratio
72.33
Ent. Value
1.33 B
Total Shares
77.74 M
Float Shares
66.51 M
Insiders
14.48%
Institutions
94.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
IART Catalyst Timeline
Dated clinical, regulatory and corporate events for Integra LifeSciences Holdings Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Integra LifeSciences Holdings Corporation
1300Total events
4Upcoming
305Tier-1 (high impact)
2002 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Poster PresentationPresentation
Poster #890 on concurrent Eustachian tube balloon dilation effects on surgical outcomes in chronic ear disease
chronic ear diseasesource ↗
●Poster PresentationPresentation
Poster #890 on concurrent Eustachian tube balloon dilation and surgical outcomes in chronic ear disease presented at AAO-HNSF 2026
chronic ear diseasesource ↗
◆Debt Royalty FinancingCorporate
Launch of proposed $600 million seven-year Senior Secured Term Loan B
▲Enrollment MilestoneTrial
100th patient enrolled in AERA Pediatric Registry
obstructive Eustachian tube dysfunction (ETD) in pediatric patientssource ↗
●R&D DayPresentation
Integra LifeSciences to feature liver surgery education at ACS Clinical Congress 2026
liver surgerysource ↗
▲Manufacturing MilestoneSurgiMendFiledCMC / Inspection
Initiated production at Braintree facility for SurgiMend relaunch
tissue reconstructionsource ↗
▼Supply DisruptionCMC / Inspection
Flood damage at Cincinnati manufacturing facility causes ~$7M revenue impact
▼Quarterly UpdateCorporate
Preliminary third quarter 2026 revenue of ~$410-412M and adjusted EPS of $0.55-$0.59
▲Manufacturing MilestoneCMC / Inspection
Initiated production at Braintree manufacturing facility
◆Oral PresentationPresentation
CFO Lea Knight presents at 2026 Jefferies Global Healthcare Conference
◆Oral PresentationPresentation
Integra LifeSciences to present at BofA Securities 2026 Health Care Conference
●Management ChangeCorporate
Stuart Essig appointed President and CEO; Michael McBreen promoted to CCO
◆Poster PresentationPriMatrixDiscontinuedPresentation
Fetal Bovine Dermal Scaffold in the Management of Mixed Thickness Burn Injuries
Burn Injuriessource ↗
◆Poster PresentationPriMatrixDiscontinuedPresentation
Performance of Fetal Bovine Dermis in Diabetic Foot Ulcers: Insights from Real-world Clinical Use
Diabetic Foot Ulcerssource ↗
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results release and conference call
◆Oral PresentationPresentation
CEO and CFO present at 44th Annual J.P. Morgan Healthcare Conference
●Manufacturing MilestoneSurgiMendFiledCMC / Inspection
Operational readiness for SurgiMend and PriMatrix manufacturing at Braintree facility expected in first-half 2026
soft tissue repairsource ↗
●Manufacturing MilestonePriMatrixDiscontinuedCMC / Inspection
Operational readiness for PriMatrix and SurgiMend manufacturing at Braintree facility expected in first-half 2026
soft tissue repairsource ↗
▼Runway Guidance UpdateCorporate
Full-year 2026 revenue guidance lowered to $1.634-1.654B and adjusted EPS to $2.30-$2.40
◆Oral PresentationPresentation
Spotlight at American Association for Thoracic Surgeon Mitral Valve Conclave
cardiac surgerysource ↗
◆Oral PresentationPresentation
CEO and CFO to present at Citi 2025 Global Healthcare Conference
▲FDA ApprovalFDA Decision
FDA 510(k) clearance for CUSA Clarity for cardiac surgeries
cardiac surgeries (debridement of unwanted tissue, including valve replacement and repair)source ↗
▲Product LaunchPriMatrixDiscontinuedPost-Market
Relaunch of PriMatrix ahead of schedule
wound reconstructionsource ↗
▲Product LaunchDurepairPost-Market
Relaunch of Durepair ahead of schedule
wound reconstructionsource ↗
●Oral PresentationPresentation
Exhibition at CNS Annual Meeting showcasing neurosurgical portfolio
▼Warning Letter IssuedCMC / Inspection
Providing regular updates to FDA on warning letter committed actions
▲First Patient DosedTrial
First patient enrolled in Acclarent AERA Pediatric Registry
obstructive Eustachian tube dysfunction (ETD)source ↗
●Trial InitiationTrial
AERA Pediatric Registry launched
obstructive Eustachian tube dysfunction (ETD) in pediatric patientssource ↗
▲Manufacturing MilestoneCMC / Inspection
Completed all manufacturing site baseline assessments under Compliance Master Plan
▲Manufacturing MilestoneCMC / Inspection
Highest-ever production rate for Integra Skin achieved
skin regenerationsource ↗
●Management ChangeCorporate
Appointed Rick Maveus as SVP of Transformation and Program Management Office
◆Oral PresentationPresentation
Presentation at Oppenheimer 35th Annual Healthcare MedTech & Services Conference
Past FDA Catalysts and PDUFA Decisions
How IART actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 85%
Micro Cap(rank 559 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every IART program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Knight Lea DanielsOfficer (EVP & Chief Financial Officer) | Disposition | -5,226 45,263 held | $18.05 | 07/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IART
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.4 % | 9.88 M | 550.00 K |
IART Institutional Ownership Trends
IART Short Interest
Shares sold short, counted twice a month.
10.93%
Short % of Float
of tradable shares sold short
7.3M
Shares Sold Short
+6.8% vs prior count
7.5 High
Days to Cover
trading days of normal volume to buy every short share back
967.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IART ranks across every disease it competes in
Competitive Position is a premium feature
See how IART ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIART News
IART▼ -11.2%on this news
Integra LifeSciences Reports Third Quarter 2026 Financial Results
Integra LifeSciences reported third quarter 2026 revenues of $411.2 million, up 2.3% from last year. The company achieved a GAAP earnings per share of $0.19, a significant improvement from a loss in the prior year. However, results were affected by a $7 million revenue loss due to flood damage at its Cincinnati facility. The company also completed a $2.1 billion debt refinancing to enhance financial flexibility.
Read more →IARTIntegra Announces Completion of Refinancing Transactions
Integra LifeSciences announced the completion of a $450 million private offering of senior secured notes due 2033 and the amendment of its existing credit facility totaling approximately $1.65 billion. The proceeds will be used to refinance the current credit facility and cover associated fees. This move is expected to enhance Integra's financial stability and operational capabilities.
Read more →IARTIntegra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting
Integra LifeSciences will participate in the 2026 AAO-HNSF Annual Meeting, highlighting its ENT technologies and instruments. The company sponsors research on Eustachian tube balloon dilation's effects on chronic ear disease outcomes. The ACCLARENT AERA system, now FDA-cleared for pediatric use, will also be featured, emphasizing Integra's commitment to advancing ENT care.
Read more →IARTIntegra Announces Pricing of Senior Secured Notes
Integra LifeSciences has announced the pricing of $450 million in senior secured notes due in 2033. The proceeds will be utilized to refinance existing credit facilities and cover related expenses. The offering is expected to close around October 19, 2026, and is part of a broader refinancing transaction.
Read more →IARTIntegra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026
Integra LifeSciences Holdings Corporation will announce its third quarter 2026 financial results on October 21, 2026. The management team will conduct a conference call at 8:30 a.m. ET to discuss the results. A live webcast will be available for investors, and a replay will be accessible afterward.
Read more →IART▼ -21.2%on this newsshared move
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
Integra LifeSciences announced preliminary third quarter results and updated its full-year guidance for 2026. The company faced challenges due to flooding at its Cincinnati facility, which impacted revenue. Despite lowering its revenue and earnings outlook, Integra remains optimistic about cash generation and recovery efforts. The company expects to return to full manufacturing operations by mid-2027.
Read more →IART▼ -21.2%on this newsshared move
Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
Integra LifeSciences has announced a proposed $600 million Senior Secured Term Loan B aimed at refinancing existing debt. The company plans to use the proceeds to improve its capital structure and maintain financial flexibility. The transaction is subject to market conditions, and there are uncertainties regarding its completion and final terms.
Read more →IARTIntegra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry
Integra LifeSciences has announced the enrollment of the 100th patient in the AERA Pediatric Registry, which aims to evaluate the Acclarent AERA Eustachian Tube Balloon Dilation System in children aged eight and older. This milestone represents one-third of the planned enrollment of 300 patients and highlights the collaboration among research teams. The registry seeks to provide real-world evidence for treating obstructive Eustachian tube dysfunction.
Read more →IARTIntegra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026
Integra LifeSciences is celebrating 20 years of its CUSA technology at the ACS Clinical Congress 2026. The event will feature educational programming led by expert liver surgeons, focusing on complex liver procedures. With a significant number of liver cancer diagnoses globally, the company emphasizes the importance of continued education in this field. Attendees can engage with the company at their booth and participate in innovative discussions.
Read more →IARTIntegra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference
Integra LifeSciences Holdings Corporation will present at two significant healthcare conferences in September 2026. CFO Lea Knight and CCO Michael McBreen will speak at the Wells Fargo Healthcare Conference, while CEO Stuart Essig will present at the Morgan Stanley Healthcare Conference. Live webcasts of these presentations will be available on their investor relations website.
Read more →IART▼ -16.5%on this news
Integra LifeSciences Reports Second Quarter 2026 Financial Results
Integra LifeSciences reported its second quarter 2026 financial results, showing a slight revenue increase of 0.8% year-over-year, totaling $418.8 million. The company achieved a significant turnaround in earnings per share, moving from a loss of $(6.31) to a profit of $0.06. Despite some declines in the Tissue Reconstruction segment, the company is reaffirming its full-year growth guidance and is set to relaunch its SurgiMend product later this year.
Read more →IART▲ +5.7%on this news
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
Integra LifeSciences Holdings Corporation will announce its second quarter 2026 financial results on July 29, 2026. The management team will conduct a conference call at 8:30 a.m. ET, which will be accessible via a live webcast. Participants are encouraged to register in advance for dial-in details.
Read more →IARTIntegra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
Integra LifeSciences has appointed Topaz Kirlew as Chief Regulatory Officer, following her interim leadership. Kirlew will oversee global regulatory affairs and has significant experience in the healthcare and medical technology sectors. Her leadership is expected to enhance the company's regulatory strategy and compliance efforts.
Read more →IARTIntegra LifeSciences Announces Key Executive Appointments
Integra LifeSciences Corporation has announced key leadership appointments to enhance its commercial organization. Mike McBreen has been appointed as executive vice president and chief commercial officer, with Robert T. Davis Jr. and Christopher Kilburn-Peterson taking on significant roles in Tissue Reconstruction. Harvinder Singh will lead the Specialty Surgery division, reflecting the company's focus on commercial excellence and internal talent development.
Read more →IARTIntegra LifeSciences to Present at the 2026 Truist Securities MedTech Conference
Integra LifeSciences Holdings Corporation announced that Bob Davis will present at the 2026 Truist Securities MedTech Conference on June 16, 2026. The presentation will focus on the company's advancements in neurosurgery and tissue reconstruction. A live webcast will be available for interested investors and stakeholders.
Read more →IARTIntegra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
Integra LifeSciences Holdings Corporation announced that its CFO, Lea Knight, will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The presentation will be available via a live webcast on the company's investor relations website. Integra is known for its innovative technologies in neurosurgery and tissue reconstruction.
Read more →IARTIntegra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
Integra LifeSciences Holdings Corporation will present at the BofA Securities 2026 Health Care Conference on May 12, 2026. CFO Lea Knight will lead the presentation, which will be available via a live webcast. The event underscores Integra's role as a leader in medical technology and its dedication to innovation in healthcare.
Read more →IART▲ +24.1%on this newsshared move
Integra LifeSciences Announces Leadership Transition
Integra LifeSciences has appointed Stuart M. Essig as its new president and chief executive officer, effective May 1, 2026, succeeding Mojdeh Poul. Essig, who has over thirty years of experience in the medical technology industry and has served as chairman of the board since June 2012, aims to enhance the company's operational resilience and customer focus. Additionally, Michael McBreen has been named chief commercial officer to further elevate the commercial organization and ensure market priorities are at the forefront of decision-making. This leadership shift is seen as pivotal for Integra's plans for 2026.
Read more →IART▲ +24.1%on this newsshared move
Integra LifeSciences Announces Leadership Transition Stuart Essig Appointed as Integra's Next President and Chief Executive Officer
Integra LifeSciences announced a leadership transition with Stuart Essig being appointed as the new president and CEO, effective May 1, 2026. Essig succeeds Mojdeh Poul, who is leaving for other opportunities. Alongside him, Michael McBreen has been appointed as chief commercial officer, tasked with enhancing the company's commercial organization. Essig, who has a long history with Integra, promised to focus on execution and customer engagement to drive long-term value.
Read more →IART▲ +24.1%on this newsshared move
Integra LifeSciences Reports First Quarter 2026 Financial Results
Integra LifeSciences reported its first quarter 2026 financial results, showing a 2.4% increase in revenues to $391.9 million. The adjusted earnings per diluted share improved to $0.54, while GAAP earnings reflected a loss of $(0.06). The company reaffirmed its full-year revenue guidance and highlighted operational improvements despite some declines in specific product segments.
Read more →About Integra LifeSciences Holdings Corporation
Headquarters1100 CAMPUS ROAD, PRINCETON, NJ, 08540
BIOPHARMAWATCH ELITE PLUS
Trade the next IART catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime